Her2 exerts its effect by forming heterodimers with other HER family members, resulting in the activation of a number of signaling pathways that are important for tumor progression and survival. Her2 overexpression has been linked with a more aggressive breast cancer phenotype and with decreased ...
Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results ...
Endocrine therapy (ET) has long been the therapeutic backbone for the treatment of HR+/HER2- breast cancer. However, for patients who already have advanced HR+/HER2- disease at the time of diagnosis, studies have shown that addition of a CDK4/6 inhibitor significantly improves outcomes compared...
Cancer Network: Dr. Pegram, what are the current HER2 therapies available for treatment of women with HER2-positive breast cancer? Dr. Pegram: Since 1998, we have had trastuzumab, which has become the mainstay of HER2-targeted breast cancer therapies for both advanced ca...
HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Approximately one of every five breast cancers have a gene mutation in the cancer cells...
Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA) trial20 is comparing T-DM1 with physician's choice of treat- ment as a third line for HER2-positive metastatic breast can- cer, although Japanese breast cancer patients are not included...
HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation? Simple Summary: In the quest for de-escalation strategies, the complete elimination of non-targeted cytotoxic chemotherapy is often considered the ultimate... N Tauber,C Cirkel,A Claussen,... - 《Cancers》 被引量: 0发表: 2024...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
Erin Frances Cobain, MD, discusses key takeaways from an OncLive Institutional Perspectives in Cancer webinar on breast cancer.
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr